Replies to post #105918 on Biotech Values

[DewDiligence]

You spent a lot of time investigating whether Teva had any IP on characterization of heparin-based drugs, and you found nothing (#msg-54443294). In #msg-54445348 you said:

The more I look at the apparent disparity in IP in the area, the more I think Teva is blowing smoke in regards to being able to copy enoxaparin to the FDA's satisfaction.

I think you were on the right track then, so I would have presumed you would want to know if Teva’s Lovenox were not Teva’s drug at all but rather something developed (and manufactured) elsewhere.